Table 1.
Sociodemographic and clinical characteristics of CHR-P individuals participating in RCTs and observational cohorts.
| n of studies (total sample) | RCTs: mean ± SD or % (95% CI) | Observational cohorts: mean ± SD or % (95% CI) | P value | |
|---|---|---|---|---|
| Age (in years) | 73 (9179) | 20.1 ± 0.9 | 20.0 ± 0.3 | 0.848 |
| Proportion of female | 72 (8,220) | 43.6 (41.3–45.9) | 45.2 (44.0–46.4) | 0.380 |
| Proportion of APS | 36 (4,745) | 84.7 (79.1–89.0) | 83.5 (82.1–84.7) | 0.193 |
| Proportion of BLIPS/BIPS | 36 (4,745) | 7.8 (4.6–13.0) | 6.4 (4.4–9.2) | 0.544 |
| Proportion of GRD | 36 (4,745) | 12.3 (4.6–29.0) | 11.3 (8.4–15.1) | 0.875 |
| Proportion of mood disorders | 12 (1,090) | 38.4 (34.1–42.8) | 49.1 (34.4–64.0) | 0.176 |
| Proportion of anxiety disorders | 24 (4,180) | 27.4 (14.5–45.8) | 29.3 (23.2–36.2) | 0.842 |
| Proportion of other substance use disordersa | 9 (1,411) | 3.4 (0.8–12.7) | 16.8 (13.3–21.0) | 0.018 |
| Proportion of antipsychotics at baseline | 32 (3,089) | 20.9 (14.7–28.8) | 26.5 (20.0–34.1) | 0.277 |
| Proportion of antidepressants at baseline | 18 (1,788) | 31.7 (14.6–55.8) | 29.6 (23.8–36.2) | 0.855 |
| Proportion of other psychotropics at baseline | 13 (1,267) | 17.2 (9.5–29.1) | 16.0 (8.1–29.2) | 0.873 |
Abbreviations: APS, attenuated psychosis symptoms; BLIPS, brief limited intermittent psychotic symptoms; CHR-P, clinical high risk of psychosis; CI, confidence intervals; GRD, genetic risk and deterioration syndrome; RCT, randomized clinical trial; SD, standard deviation.
a
Excluding alcohol use disorders and cannabis use disorder.Bold values indicate p<0.05.